These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7298876)

  • 1. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations.
    Diasio RB; Ettinger DS; Satterwhite BE
    J Clin Pharmacol; 1981; 21(S1):81S-85S. PubMed ID: 7298876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy.
    Cronin CM; Sallan SE; Gelber R; Lucas VS; Laszlo J
    J Clin Pharmacol; 1981; 21(S1):43S-50S. PubMed ID: 7028793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration.
    Laszlo J; Lucas VS; Hanson DC; Cronin CM; Sallan SE
    J Clin Pharmacol; 1981; 21(S1):51S-56S. PubMed ID: 7298875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine.
    Sheidler VR; Ettinger DS; Diasio RB; Enterline JP; Brown MD
    J Clin Pharmacol; 1984 Apr; 24(4):155-9. PubMed ID: 6373843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of refractory cytostatic agent-induced vomiting with the synthetic cannabinoid levonantradol].
    Heim ME; Queisser W
    Onkologie; 1982 Apr; 5(2):94-6. PubMed ID: 7048169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis.
    Stambaugh JE; McAdams J; Vreeland F
    J Clin Pharmacol; 1984; 24(11-12):480-5. PubMed ID: 6392353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
    Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
    Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting.
    Heim ME; Romer W; Queisser W
    J Clin Pharmacol; 1981; 21(S1):86S-89S. PubMed ID: 7298877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.
    Joss RA; Galeazzi RL; Bischoff A; Do DD; Goldhirsch A; Brunner KW
    Cancer Chemother Pharmacol; 1982; 9(1):61-4. PubMed ID: 7139853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
    Heim ME; Queisser W; Altenburg HP
    Cancer Chemother Pharmacol; 1984; 13(2):123-5. PubMed ID: 6467496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
    Stuart-Harris RC; Mooney CA; Smith IE
    Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.
    Gerhartz HH; Binsack T; Hiller E
    Klin Wochenschr; 1983 Jul; 61(14):719-21. PubMed ID: 6350696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of levonantradol in chemotherapy-induced emesis.
    Tyson LB; Gralla RJ; Clark RA; Kris MG; Bordin LA; Bosl GJ
    Am J Clin Oncol; 1985 Dec; 8(6):528-32. PubMed ID: 4083271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
    Hutcheon AW; Palmer JB; Soukop M; Cunningham D; McArdle C; Welsh J; Stuart F; Sangster G; Kaye S; Charlton D
    Eur J Cancer Clin Oncol; 1983 Aug; 19(8):1087-90. PubMed ID: 6352278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levonantradol as an antiemetic in cancer chemotherapy].
    Mella O; Følling Elgjo R; Isaksen H; Klepp O
    Tidsskr Nor Laegeforen; 1984 Nov; 104(33):2320-2. PubMed ID: 6523465
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral levonantradol in the control of cancer chemotherapy-induced emesis.
    Welsh J; Stuart F; Sangster G; Milstead R; Kaye S; Cash H; Charlton D; Calman K
    Cancer Chemother Pharmacol; 1983; 11(1):66-7. PubMed ID: 6684000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis.
    Voravud N; Suwanrusmee H
    J Med Assoc Thai; 2000 Jun; 83(6):668-75. PubMed ID: 10932495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics.
    Kenny JB; Wilkinson PM
    Clin Oncol; 1982 Dec; 8(4):335-9. PubMed ID: 7168926
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.